0RY.F Rhythm Biosciences Limited

Healthcare Diagnostics & Research Frankfurt Exchange
0.0380 EUR
Close of Nov 11, 2026
0.0370 0.1440
Market cap
EUR 13.4M
P/E
-
P/B
6.39x
ROE
-163.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is 0RY.F undervalued?

Graham number

The Graham number of Rhythm Biosciences Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rhythm Biosciences Limited fundamental analysis

No fundamental analysis for Rhythm Biosciences Limited yet.

Rhythm Biosciences Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rhythm Biosciences Limited

Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

Full company profile